Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny zap behind the ear tame migraine dizziness?

NCT ID NCT07368140

Symptom relief Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a new, non-drug treatment for vestibular migraine, a condition causing repeated dizziness and headaches. Fifty adults will receive either real or sham electrical stimulation behind the ears over six sessions. The main goal is to see if the treatment is safe and tolerable, and to gather early data on symptom improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electrical vestibular stimulation (gentle electrical signals behind the ears)
What this could lead to
If it works, this could point toward a drug-free treatment for vestibular migraine, reducing dizziness and headaches.
What could go wrong
This is a very early pilot study with only 50 people. It is designed mainly to test safety and feasibility, not to prove effectiveness. The sham group may show similar results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of VM, according to the ICHD-3 and Barany Society criteria. * Experienced at least one vestibular migraine episode in the previous month. * Ability to provide informed consent and comply with study requirements. * Willingness to attend six EVS sessions over a two-week period and complete all required testing and diaries. * Physical ability to stand unassisted for at least one minute and walk 25 feet without assistance. Exclusion Criteria: * Diagnosis of other vestibular disorders (e.g. benign paroxysmal positional vertigo, Meniere's disease, vestibular neuritis) that may confound results. * History of seizure disorder, epilepsy, or unexplained loss of consciousness. * Presence of implanted electronic medical devices, such as pacemakers or cochlear implants. * Pregnancy or plans to become pregnant during study period. * Use of vestibular suppressant or migraine prophylactic medications that cannot be paused or maintained at a stable dose during the two-week EVS intervention period. Acute use of rescue medications during a severe attack is permitted, however, participants who initiate new medication or undergo dose changes during the intervention window will be excluded from final analysis. * Current medical, psychiatric, or neurological condition (other than VM) that could interfere with participation. * Cognitive or language impairments that preclude understanding of instructions or valid completion of outcome measures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vestibular migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dizziness migraine with brainstem aura Vertigo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vestibular migraine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Human Performance Laboratory, University of Calgary

    Calgary, Alberta, T2N 1N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.